Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity

Wei Chi Wu; Chia Pang Shih; Reyin Lien; Nan Kai Wang; Yen Po Chen; An Ning Chao; Kuan Jen Chen; Tun Lu Chen; Yih Shiou Hwang; Chi Chun Lai

doi:10.1097/IAE.0000000000001209

Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity

Wei Chi Wu^*
, Chia Pang Shih
, Reyin Lien
, Nan Kai Wang
, Yen Po Chen
, An Ning Chao
, Kuan Jen Chen
, Tun Lu Chen
, Yih Shiou Hwang
, Chi Chun Lai

^*Corresponding author for this work

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

124 Scopus citations

Abstract

Purpose: To investigate vascular endothelial growth factor (VEGF) levels in the systemic circulation after intravitreal injections of bevacizumab (IVB) or ranibizumab (IVR) in patients with Type 1 retinopathy of prematurity (ROP). Methods: Patients who had Type 1 ROP and received IVB or IVR were enrolled. Serum samples were collected before and up to 12 weeks after IVB or IVR treatment. The main outcome measurements were serum levels of VEGF up to 12 weeks after anti-VEGF treatment. Results: In total, 10 patients with Type 1 ROP were enrolled in this study. All the eyes had complete resolution of abnormal neovascularization of ROP after IVB or IVR. In the direct comparison of IVB with IVR, serum VEGF was found to be suppressed more in patients with Type 1 ROP who received IVB treatment, compared with those who received IVR treatment (P = 0.01, P = 0.03, and P = 0.03, respectively, 2, 4, and 8 weeks after intravitreal injection). Conclusion: Serum VEGF levels in patients with Type 1 ROP were suppressed for 2 months after treatment with IVB, and VEGF levels were less affected after IVR treatment. Further studies are warranted to investigate the long-term effects of VEGF changes in ROP patients.

Original language	English
Pages (from-to)	694-701
Number of pages	8
Journal	Retina
Volume	37
Issue number	4
DOIs	https://doi.org/10.1097/IAE.0000000000001209
State	Published - 2017

Bibliographical note

Publisher Copyright:
© by Opthalmic Communications Society, Inc.

Keywords

Intravitreal injections of bevacizumab
Intravitreous injections of ranibizumab
Retinopathy of prematurity
Serum
Vascular endothelial growth factor

Access to Document

10.1097/IAE.0000000000001209

Cite this

@article{62654a5aa44e48c0b6ce4b7f36c47444,

title = "Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity",

abstract = "Purpose: To investigate vascular endothelial growth factor (VEGF) levels in the systemic circulation after intravitreal injections of bevacizumab (IVB) or ranibizumab (IVR) in patients with Type 1 retinopathy of prematurity (ROP). Methods: Patients who had Type 1 ROP and received IVB or IVR were enrolled. Serum samples were collected before and up to 12 weeks after IVB or IVR treatment. The main outcome measurements were serum levels of VEGF up to 12 weeks after anti-VEGF treatment. Results: In total, 10 patients with Type 1 ROP were enrolled in this study. All the eyes had complete resolution of abnormal neovascularization of ROP after IVB or IVR. In the direct comparison of IVB with IVR, serum VEGF was found to be suppressed more in patients with Type 1 ROP who received IVB treatment, compared with those who received IVR treatment (P = 0.01, P = 0.03, and P = 0.03, respectively, 2, 4, and 8 weeks after intravitreal injection). Conclusion: Serum VEGF levels in patients with Type 1 ROP were suppressed for 2 months after treatment with IVB, and VEGF levels were less affected after IVR treatment. Further studies are warranted to investigate the long-term effects of VEGF changes in ROP patients.",

keywords = "Intravitreal injections of bevacizumab, Intravitreous injections of ranibizumab, Retinopathy of prematurity, Serum, Vascular endothelial growth factor",

author = "Wu, \{Wei Chi\} and Shih, \{Chia Pang\} and Reyin Lien and Wang, \{Nan Kai\} and Chen, \{Yen Po\} and Chao, \{An Ning\} and Chen, \{Kuan Jen\} and Chen, \{Tun Lu\} and Hwang, \{Yih Shiou\} and Lai, \{Chi Chun\}",

note = "Publisher Copyright: {\textcopyright} by Opthalmic Communications Society, Inc.",

year = "2017",

doi = "10.1097/IAE.0000000000001209",

language = "英语",

volume = "37",

pages = "694--701",

journal = "Retina",

issn = "0275-004X",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity

AU - Wu, Wei Chi

AU - Shih, Chia Pang

AU - Lien, Reyin

AU - Wang, Nan Kai

AU - Chen, Yen Po

AU - Chao, An Ning

AU - Chen, Kuan Jen

AU - Chen, Tun Lu

AU - Hwang, Yih Shiou

AU - Lai, Chi Chun

N1 - Publisher Copyright: © by Opthalmic Communications Society, Inc.

PY - 2017

Y1 - 2017

N2 - Purpose: To investigate vascular endothelial growth factor (VEGF) levels in the systemic circulation after intravitreal injections of bevacizumab (IVB) or ranibizumab (IVR) in patients with Type 1 retinopathy of prematurity (ROP). Methods: Patients who had Type 1 ROP and received IVB or IVR were enrolled. Serum samples were collected before and up to 12 weeks after IVB or IVR treatment. The main outcome measurements were serum levels of VEGF up to 12 weeks after anti-VEGF treatment. Results: In total, 10 patients with Type 1 ROP were enrolled in this study. All the eyes had complete resolution of abnormal neovascularization of ROP after IVB or IVR. In the direct comparison of IVB with IVR, serum VEGF was found to be suppressed more in patients with Type 1 ROP who received IVB treatment, compared with those who received IVR treatment (P = 0.01, P = 0.03, and P = 0.03, respectively, 2, 4, and 8 weeks after intravitreal injection). Conclusion: Serum VEGF levels in patients with Type 1 ROP were suppressed for 2 months after treatment with IVB, and VEGF levels were less affected after IVR treatment. Further studies are warranted to investigate the long-term effects of VEGF changes in ROP patients.

AB - Purpose: To investigate vascular endothelial growth factor (VEGF) levels in the systemic circulation after intravitreal injections of bevacizumab (IVB) or ranibizumab (IVR) in patients with Type 1 retinopathy of prematurity (ROP). Methods: Patients who had Type 1 ROP and received IVB or IVR were enrolled. Serum samples were collected before and up to 12 weeks after IVB or IVR treatment. The main outcome measurements were serum levels of VEGF up to 12 weeks after anti-VEGF treatment. Results: In total, 10 patients with Type 1 ROP were enrolled in this study. All the eyes had complete resolution of abnormal neovascularization of ROP after IVB or IVR. In the direct comparison of IVB with IVR, serum VEGF was found to be suppressed more in patients with Type 1 ROP who received IVB treatment, compared with those who received IVR treatment (P = 0.01, P = 0.03, and P = 0.03, respectively, 2, 4, and 8 weeks after intravitreal injection). Conclusion: Serum VEGF levels in patients with Type 1 ROP were suppressed for 2 months after treatment with IVB, and VEGF levels were less affected after IVR treatment. Further studies are warranted to investigate the long-term effects of VEGF changes in ROP patients.

KW - Intravitreal injections of bevacizumab

KW - Intravitreous injections of ranibizumab

KW - Retinopathy of prematurity

KW - Serum

KW - Vascular endothelial growth factor

UR - https://www.scopus.com/pages/publications/84980017972

U2 - 10.1097/IAE.0000000000001209

DO - 10.1097/IAE.0000000000001209

M3 - 文章

C2 - 27467377

AN - SCOPUS:84980017972

SN - 0275-004X

VL - 37

SP - 694

EP - 701

JO - Retina

JF - Retina

IS - 4

ER -

Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this